XML 70 R56.htm IDEA: XBRL DOCUMENT v3.10.0.1
License Agreements - Agenus (Details)
$ / shares in Units, $ in Thousands, shares in Millions
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Feb. 14, 2017
USD ($)
$ / shares
Feb. 01, 2017
USD ($)
$ / shares
shares
Feb. 18, 2015
USD ($)
Sep. 30, 2018
USD ($)
Jun. 30, 2018
USD ($)
Feb. 28, 2017
USD ($)
item
Nov. 30, 2015
item
Feb. 28, 2015
Sep. 30, 2018
USD ($)
Sep. 30, 2017
USD ($)
Sep. 30, 2018
USD ($)
Sep. 30, 2017
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
License agreements                              
Long term investment                         $ 99,199 $ 134,356  
Research and development expense                         1,197,957 1,326,134 $ 581,861
Unrealized gain (loss) on long term investments                         (44,093) (24,275) (3,261)
Current assets                         1,832,254 1,504,854  
Current liabilities                         425,277 375,396  
Cash and cash equivalents                         $ 1,163,980 899,509  
Agenus                              
License agreements                              
Number of program targets | item           4 3                
Royalty payments on future global net sales (as a percent)                         15.00%    
Research and development expense                         $ 4,600 19,500 17,500
Agenus | Accrued and other liabilities                              
License agreements                              
Accrued and other liabilities                         $ 2,300 3,200  
Agenus | Development, Regulatory and Commercialization Milestones | Minimum                              
License agreements                              
Royalty payments on future global net sales (as a percent)                         6.00%    
Agenus | Development, Regulatory and Commercialization Milestones | Maximum                              
License agreements                              
Royalty payments on future global net sales (as a percent)                         12.00%    
Additional milestone payments under the license agreement           $ 510,000                  
Agenus | Development Milestones                              
License agreements                              
Upfront payment under license agreement       $ 5,000 $ 5,000 $ 20,000                  
Agenus                              
License agreements                              
Long term investment                         $ 42,300 57,900  
Shares owned following stock purchase (as a percent)           11.00%   9.00%              
Ownership percentage (as a percent)                         15.00%    
Unrealized gain (loss) on long term investments                         $ (15,600) (13,600) $ (3,300)
Total revenues                 $ 12,800 $ 3,400 $ 30,300 $ 34,500      
Net income (loss)                 (33,700) $ (36,800) (113,200) $ (85,700)      
Current assets       67,600         67,600   67,600     73,600  
Noncurrent assets       62,800         62,800   62,800     64,800  
Current liabilities       58,200         58,200   58,200     56,400  
Noncurrent liabilities       $ 203,700         $ 203,700   $ 203,700     157,800  
Agenus | Stock purchase agreement                              
License agreements                              
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares   10.0                          
Purchase price of common stock   $ 60,000                          
Per share price | $ / shares $ 4.40 $ 6.00                          
Discount for lack of marketability $ 4,500                            
Fair value of shares on the issuance date 39,500                            
Total consideration paid $ 60,000   $ 60,000                        
Long term investment                           39,500  
Research and development expense                           $ 20,500